唑来膦酸治疗绝经后骨质疏松症临床疗效的研究

发布时间：2018-06-19 17:06

  本文选题：绝经后骨质疏松症 + 唑来膦酸　； 参考：《浙江大学》2017年硕士论文

【摘要】：目的:研究分析使用唑来膦酸治疗66例绝经后女性骨质疏松症患者的临床疗效。方法:选择2012-2016年间在我院骨科住院行静脉滴注唑来膦酸治疗的绝经后女性骨质疏松症患者共66例,年龄范围51-97岁,平均(68.606±8.621)岁。患者使用唑来膦酸(密固达)5mg(100ml)静脉滴注1次,滴注时间15min以上,并且患者每天基础服用骨矿化促进药物骨化三醇0.5μg/d及碳酸钙片1片/天。在使用唑来膦酸治疗前、治疗1年后分别检测患者腰椎总骨密度、右侧髋关节骨密度,以及血清总Ⅰ型胶原氨基酸延长肽(t-P11NP)、N端骨钙素(N-MID)、β-胶原特殊序列(β-CTX)、25-羟基维生素D(25-OH-VD)这些骨代谢指标,并对检测结果进行统计分析。比较患者骨密度、血清骨代谢指标在治疗前后的变化差异,以及在各年龄段(51-60岁,61-70岁,70岁以上)治疗前后的差异。□□结果:患者腰椎总骨密度、血清总Ⅰ型胶原氨基酸延长肽、N端骨钙素、β-胶原特殊序列、25-羟基维生素D在治疗1年后与治疗前相比有显著差异(P0.05)。全髋关节骨密度在治疗1年后与治疗前比较,虽有所增加,但差异却无统计学意义(P0.05)。51-60岁,61-70岁,70岁以上三个年龄分组中腰椎总骨密度、血清总Ⅰ型胶原氨基酸延长肽、N端骨钙素、β-胶原特殊序列、25-羟基维生素D在治疗1年后与治疗前相比均有显著差异(P0.05)。而右氈关节骨密度与治疗前比较虽均有增加,但差异无统计学意义(P0.05)。结论:静脉滴注唑来膦酸治疗绝经后女性骨质疏松症,不仅能有效提高患者腰椎的总骨密度,同时也可改善患者的血清中骨代谢指标,并且对各年龄段的绝经后骨质疏松症女性均有明确的临床效果。
[Abstract]:Objective: To study and analyze the clinical efficacy of zoledronic acid in the treatment of 66 postmenopausal women with osteoporosis. Methods: 66 cases of postmenopausal women with postmenopausal osteoporosis treated in 2012-2016 years in our department of orthopedics were treated with zazolonic acid. The average age range was 51-97 years old (68.606 + 8.621) years. The patients were treated with zoledrine. Acid (dense) 5mg (100ml) intravenous infusion 1 times, infusion time more than 15min, and patients on a daily basis of bone mineralization to promote ossification of three alcohol 0.5 mu g/d and Calcium Carbonate Tablets 1 tablets / days. Before the treatment of zoledronic acid, the total bone mineral density, right hip joint bone density, and serum total type I collagen amino group were detected 1 years before the treatment of zoledronic acid. Acid lengthening peptide (t-P11NP), N terminal Osteocalcin (N-MID), beta collagen special sequence (beta -CTX) and 25- hydroxyl vitamin D (25-OH-VD) were used to analyze the bone metabolic indices, and to compare the results of bone mineral density and serum bone metabolism before and after treatment (51-60 years old, 61-70 years old, over 70 years old). Results: the total BMD of the lumbar spine, the total serum type I collagen amino acid lengthening peptide, the N end osteocalcin, the special sequence of beta collagen, and the 25- hydroxyvitamin D were significantly different from those before the treatment (P0.05). The total hip joint bone density was increased after 1 years of treatment, although the difference was not statistically significant. The total BMD of lumbar vertebrae in P0.05.51-60 years, 61-70 years old and over 70 years old in three age groups, serum total type I collagen amino acid lengthening peptide, N end osteocalcin, and beta collagen special sequence, 25- hydroxyl vitamin D were significantly different from before treatment (P0.05) compared with before treatment (P0.05), but the right felt joint bone density increased although compared with before treatment, but poor There is no statistical significance (P0.05). Conclusion: intravenous drip of zoledronic acid in the treatment of postmenopausal women osteoporosis can not only improve the total bone mineral density of the lumbar spine, but also improve the index of bone metabolism in the patients' serum, and have a clear clinical effect on postmenopausal women with osteoporosis.
【学位授予单位】：浙江大学
【学位级别】：硕士
【学位授予年份】：2017
【分类号】：R580
，

本文编号：2040600